91ÑÇÉ«´«Ã½

Derek Abbott

is a physician–scientist at Case Western Reserve University, where his lab mines autoinflammatory disease genetics to unlock novel targets for pharmaceutical intervention in inflammation. His first manuscript as a graduate student was published in JBC, and his lab continues to submit their work to the journal. He said that he’s “thrilled and humbled to be an editorial board member at this historic journal.” He has been on the board since 2016.

Millie Georgiadis

is a professor and vice chair of research at Indiana University School of Medicine. She specializes in X-ray crystallography and complementary biochemistry of systems involving protein-nucleic acid interactions. “Especially in these times, it is important to focus on high standards for our science to ensure that we are making meaningful and impactful contributions,” Georgiadis said, adding that she approaches each manuscript she reviews with “an open mind and spends sufficient time to fully appreciate the scientific story and the details that support that story,” because, as an author, she appreciates “thoughtful comments from reviewers that will help me improve a manuscript.” Georgiadis has been a board member since 2021.

Birte Svensson

is a professor at the Technical University of Denmark.  Her main research interests are structure/function relationships and applications of multidomain carbohydrate active enzymes acting on starch, alginate and other dietary polysaccharide fibers, proteins and hydrocolloids in food and dairy. Svensson has been a member of the board since 2014.

Matthew Kimber

runs a structural biochemistry lab at the University of Guelph. His research focuses on the architecture, structure, mechanisms and diversity of the proteins that assemble bacterial cell-surface polysaccharides. He also has worked on a variety of other systems, including carbonic anhydrases, carboxysomes, steroid degradation pathways and bacterial cell-division proteins. He has been on the board since 2020.

Paul Shapiro

is a professor and associate dean at the University of Maryland’s pharmacy school. His team is pursuing novel approaches to modulate the functions of protein kinases involved in cancer and inflammatory disorders. Shapiro’s research, conducted in collaboration with colleagues at the pharmacy and medical schools, has led to the discovery of novel kinase inhibitors now in phase II clinical trials for the treatment of acute respiratory distress syndrome. He has been a JBC editorial board member since 2013 and said he is grateful to be a part of a rigorous peer-review process that strives to be fair and constructive.

Aziz Sancar

is a physician-scientist at the medical school of the University of North Carolina at Chapel Hill. His lab specializes in DNA repair, cell-cycle checkpoints and circadian clock. In 2015, he won the Nobel Prize in Chemistry along with Tomas Lindahl and Paul L. Modrich for their mechanistic studies of DNA repair. He has been a loyal supporter and advocate for JBC; in fact, he has published more than 100 papers in the journal and contributed a 2021 “Reflections” about that milestone. He has been on the board since 2014.

David Ford

is a professor and directs the Center for Cardiovascular Research at St. Louis University. His lab studies vascular disease and organ failure. More specifically, it investigates the biology of lipid oxidation products with a focus on endothelial and epithelial dysfunction during sepsis and in response to environmental inhalation injury. He has been on the board since 2021.

Scott Gordon

is an assistant professor at the University of Kentucky College of Medicine, where he established his laboratory in the Saha Cardiovascular Research Center in 2018. His research program is focused on various aspects of lipoprotein metabolism in cardiovascular and metabolic diseases. Specifically, his team is exploring mechanisms involved in dietary lipid absorption that impact metabolic health and the roles of plasma lipoproteins in atherosclerosis. Recently, Gordon was identified as a “Rising Star in the Lipid Field” by JLR, and he was a finalist for the Irvine H. Page Junior Faculty Research Award from the American Heart Association. Gordon has served as an ad hoc reviewer for over 20 different journals and is currently a junior associate editor for JLR.

Bing Zhang

is an internationally recognized leader in computational cancer proteogenomics at Baylor College of Medicine. His lab is developing informatics solutions that help translate cancer genomic and proteomic data into biological and clinical insights. Studies by his team have demonstrated the power of proteogenomics in advancing cancer biology, diagnosis and treatment. He has been on the board since 2018.